To overcome the industry bottleneck of few validated solid tumor targets (15-20), Memo analyzes tumor-infiltrating B-cells from patients with superior outcomes. This approach aims to identify unique antibody-target pairs, unlocking new biological pathways for next-generation therapies like ADCs and CAR-Ts.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

Contrary to the belief that AI needs massive datasets, Dr. Joseph Juraji's approach with NetraAI focuses on finding small, specific patient subpopulations within small trials. This allows the identification of a drug's 'superpower' without the need for big data, transforming trial economics.

The standard approach to reducing cancer drug toxicity is narrowing the target to specific mutations (e.g., HER2, KRAS). While this improves safety, it drastically shrinks the addressable patient population for each new therapy. This puts immense pressure on the pharmaceutical business model, where development costs average $2.5 billion per drug.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

A major cause of clinical trial failure is that preclinical testing uses immortalized cancer cell lines cultured for decades. These cells have abnormal genomes and gene expressions that don't represent actual tumors, creating a massive translational gap that Noetik's patient-derived data aims to solve.

Despite billions invested over 20 years in targeted and genome-based therapies, the real-world benefit to cancer patients has been minimal, helping only a small fraction of the population. This highlights a profound gap and the urgent need for new paradigms like functional precision oncology.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

A-muto's CEO argues that shaving months off discovery isn't the real prize. The massive cost in drug development comes from late-stage clinical failures. By selecting highly disease-specific targets upfront, their platform aims to reduce the high attrition rate in clinical trials, which is the true driver of cost and delay.